Submission Guidelines

• Deadline: December 19, 2026
• Submission: Email your abstract to This email address is being protected from spambots. You need JavaScript enabled to view it.. Please include the curriculum vitae (CV) of the presenting author in the submission.

Abstract Guidelines

• Languages: Prepare your abstract and poster in English. GVIRF will be conducted primarily in English, with simultaneous translation into Arabic and French in the plenary sessions.
• Title: Please submit the title exactly as you wish it to be presented in the program (maximum 20 words). Ensure that the title effectively conveys the primary message of your study.
• Authors: Include all contributing authors in your abstract submission. Indicate which author will be presenting the poster.
• Structure: Abstracts should contain the following sections: Introduction, Methods, Results, and Conclusions.
• Length: 250 to 500 words

Accepted applicants will be notified by email in February 2027. Preference will be given to early-career scientists from the region and representatives from vaccine manufacturers in developing countries. Presenting authors of accepted abstracts will be invited to prepare a poster. If your abstract is accepted, GVIRF will cover travel expenses, subject to WHO travel policies.

If you have any questions, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..

GVIRF-next

This resource appears in the following Hot Topic page:

• Global Vaccine and Immunization Research Forum (GVIRF)

The resource is included in the following table: